These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 16482237)

  • 21. [Hepatitis C in Germany: an analysis of statutory sickness funds claims data].
    Tomeczkowski J; Cornberg M
    Dtsch Med Wochenschr; 2015 Apr; 140(8):e67-73. PubMed ID: 25945914
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Outcome of treatment with peg-interferon and ribavirin in HIV-HCV co-infected patients: "real life" single center experience].
    Veitsman E; Shahar E; Hassoun G; Lorber M; Kramskay R; Maor C; Pollack S; Baruch Y
    Harefuah; 2012 Dec; 151(12):684-7, 721, 720. PubMed ID: 23330260
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus-HCV coinfected patients: one more argument for expanded access to HCV treatment for injecting drug users.
    Roux P; Fugon L; Winnock M; Salmon-Céron D; Lacombe K; Sogni P; Spire B; Dabis F; Carrieri MP;
    Addiction; 2012 Jan; 107(1):152-9. PubMed ID: 21819472
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adoption of direct-acting antiviral medications for hepatitis C: a retrospective observational study.
    Zullig LL; Bhatia HL; Gellad ZF; Eatherly M; Henderson R; Bosworth HB
    BMC Health Serv Res; 2019 Jul; 19(1):521. PubMed ID: 31345218
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decentralised hepatitis C testing and treatment in rural Cambodia: evaluation of a simplified service model integrated in an existing public health system.
    Zhang M; O'Keefe D; Craig J; Samley K; Bunreth V; Jolivet P; Balkan S; Marquardt T; Dousset JP; Le Paih M
    Lancet Gastroenterol Hepatol; 2021 May; 6(5):371-380. PubMed ID: 33743883
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predicting the impact of adverse events and treatment duration on medical resource utilization-related costs in hepatitis C genotype 1 treatment-naïve patients receiving antiviral therapy.
    Akpo EI; Cerri K; Kleintjens J
    Pharmacoeconomics; 2015 Apr; 33(4):409-22. PubMed ID: 25577042
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients.
    Rosso C; Abate ML; Ciancio A; Strona S; Caviglia GP; Olivero A; Touscoz GA; Rizzetto M; Pellicano R; Smedile A
    World J Gastroenterol; 2014 Sep; 20(36):13146-52. PubMed ID: 25278709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of treatment of hepatitis C virus infection in renal transplant recipients.
    Aljumah AA; Saeed MA; Al Flaiw AI; Al Traif IH; Al Alwan AM; Al Qurashi SH; Al Ghamdi GA; Al Hejaili FF; Al Balwi MA; Al Sayyari AA
    World J Gastroenterol; 2012 Jan; 18(1):55-63. PubMed ID: 22228971
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
    Hartwell D; Jones J; Baxter L; Shepherd J
    Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A population approach to disease management: hepatitis C direct-acting antiviral use in a large health care system.
    Belperio PS; Backus LI; Ross D; Neuhauser MM; Mole LA
    J Manag Care Spec Pharm; 2014 Jun; 20(6):533-40. PubMed ID: 24856591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load.
    Neukam K; Camacho A; Caruz A; Rallón N; Torres-Cornejo A; Rockstroh JK; Macías J; Rivero A; Benito JM; López-Cortés LF; Nattermann J; Gómez-Mateos J; Soriano V; Pineda JA
    J Hepatol; 2012 Apr; 56(4):788-94. PubMed ID: 22173157
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patients.
    Tural C; Galeras JA; Planas R; Coll S; Sirera G; Giménez D; Salas A; Rey-Joly C; Cirera I; Márquez C; Tor J; Videla S; García-Retortillo M; Clotet B; Solà R
    Antivir Ther; 2008; 13(8):1047-55. PubMed ID: 19195330
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Strategies for assignment of HIV-HCV genotype-1-coinfected patients to either dual-therapy or direct-acting antiviral agent-based triple-therapy.
    Mandorfer M; Neukam K; Rivero A; Puoti M; Boesecke C; Baumgarten A; Grzeszczuk A; Zangerle R; Ernst D; Rockstroh JK; Trauner M; Pineda JA; Peck-Radosavljevic M; Reiberger T
    Antivir Ther; 2014; 19(4):407-14. PubMed ID: 24342953
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV.
    Rivero-Juarez A; Mira JA; Camacho A; Neukam K; Perez-Camacho I; Caruz A; Macias J; Torre-Cisneros J; Pineda JA; Rivero A
    Infection; 2013 Feb; 41(1):21-6. PubMed ID: 23065463
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of an induction period of pegylated interferon-α2a and ribavirin on early virological response in HIV-HCV-coinfected patients: results from the CORAL-2 study.
    Tural C; Solà R; Alvarez NP; Moltó J; Sánchez M; Zamora AM; Ornelas A; Laguno M; González J; von Wichmann MÁ; Téllez MJ; Paredes R; Clotet B;
    Antivir Ther; 2011; 16(6):833-41. PubMed ID: 21900715
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis.
    Kalafateli M; Buzzetti E; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011644. PubMed ID: 28285495
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Noncompliance with guidelines for the treatment of hepatitis C is frequent in daily practice.
    Niederau C; Mauss S; Böker K; Lutz T; Heyne R; Moog G; John C; Witthöft T; Alshuth U; Hüppe D
    Eur J Gastroenterol Hepatol; 2014 Jan; 26(1):65-73. PubMed ID: 23751351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of characteristics of treated and non-treated patients with Hepatitis C infection.
    Hare CB; Morris JA; Chu A; Gotz V; Loveland JJ; Hodes D; Klaskala W
    Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):71-6. PubMed ID: 16136612
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single-dose infliximab in hepatitis C genotype 1 treatment-naive patients with high serum tumour necrosis factor-alpha does not influence the efficacy of pegylated interferon alpha-2b/ribavirin therapy.
    Cooper C; Shafran S; Greenbloom S; Enns R; Farley J; Hilzenrat N; Williams K; Elkashab M; Abadir N; Neuman M
    Can J Gastroenterol Hepatol; 2014 Jan; 28(1):35-40. PubMed ID: 24212915
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection.
    Grebely J; Genoway K; Khara M; Duncan F; Viljoen M; Elliott D; Raffa JD; DeVlaming S; Conway B
    Int J Drug Policy; 2007 Oct; 18(5):437-43. PubMed ID: 17854734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.